Last reviewed · How we verify
Tat
Tat is a therapeutic vaccine based on the HIV Tat protein designed to boost immune responses against HIV-infected cells.
Tat is a therapeutic vaccine based on the HIV Tat protein designed to boost immune responses against HIV-infected cells. Used for HIV infection (therapeutic vaccine in combination with antiretroviral therapy).
At a glance
| Generic name | Tat |
|---|---|
| Sponsor | Barbara Ensoli, MD |
| Drug class | Therapeutic vaccine |
| Target | HIV Tat protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Tat (transactivator of transcription) is an HIV regulatory protein that is expressed on the surface of HIV-infected cells. The Tat vaccine aims to induce cellular and humoral immune responses against Tat-expressing cells, potentially controlling viral replication and delaying disease progression. This approach leverages the fact that Tat is essential for HIV replication and is a target of natural immune responses in some long-term non-progressors.
Approved indications
- HIV infection (therapeutic vaccine in combination with antiretroviral therapy)
Common side effects
- Local injection site reactions
- Systemic immune activation
Key clinical trials
- Extended Follow-Up of the ISS T-003 Trial Volunteers (ISS T-003 EF-UP2020)
- Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4) (NA)
- Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study (PHASE3)
- Non-invasive Evaluation of Graft Condition in Adult Patients With Kidney Transplant Using Ultrasound Localization Microscopy and Multispectral Optoacoustic Tomography
- A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours (PHASE1)
- A Study of Tumor Imaging With Multispectral Optoacoustic Tomography
- Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer (NA)
- Optoacoustic Detection of Inflammation Using MSOT Device (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tat CI brief — competitive landscape report
- Tat updates RSS · CI watch RSS
- Barbara Ensoli, MD portfolio CI